Pharmacogenetics of ranibizumab on diabetic retinopathy
Main Article Content
Keywords
Pharmacogenetics, ranibizumab, VEGF, diabetic retinopathy
Abstract
Diabetes is the leading prevalent worldwide metabolic disease and a growing global problem. Diabetic retinopathy (DR) is the most common microvascular complication of diabetes and, several years after its onset, leads to the development of macular oedema (DME). Ranibizumab is highly effective in the treatment of DME, but some cases have failed to respond well to this drug, resulting in severe visual loss. VEGF-A polymorphisms may be the reason for the patients’ poor response to ranibizumab. In the near future, gene therapy may become a part of routine clinical practice for DR. Further research in the field of pharmacogenetics and gene therapy is required to realize the full potential and limitations of this strategy.
References
2. Wang W, Lo ACY. Diabetic retinopathy: Pathophysiology and treatments. Int J Mol Sci. 2018;19(6).
3. Moutray T, Evans JR, Lois N, Armstrong DJ, Peto T, Azuara-Blanco A. Different lasers and techniques for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2018;2018(3).
4. Robin Jump Nicolas W. Cortes-Penfield BWT. 乳鼠心肌提取 HHS Public Access. Physiol Behav. 2017;176(5):139–48.
5. Sivaprasad S, Prevost AT, Vasconcelos JC, Riddell A, Murphy C, Kelly J, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, n. Lancet. 2017;389(10085):2193–203.
6. Melincovici CS, Boşca AB, Şuşman S, Mărginean M, Mihu C, Istrate M, et al. Vascular endothelial growth factor (VEGF) – key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59(2):455–67.
7. Araújo RS, Bitoque DB, Silva GA. Dual-Acting Antiangiogenic Gene Therapy Reduces Inflammation and Regresses Neovascularization in Diabetic Mouse Retina. Mol Ther - Nucleic Acids [Internet]. 2020;22(December):329–39. Available from: https://doi.org/10.1016/j.omtn.2020.08.036
8. Yang Q, Zhang Y, Zhang X, Li X, Liu J. Association of VEGF Gene Polymorphisms with Susceptibility to Diabetic Retinopathy: A Systematic Review and Meta-Analysis. Horm Metab Res. 2020;52(5):264–79.
9. Qiu M, Xiong W, Liao H, Li F. VEGF -634G>C polymorphism and diabetic retinopathy risk: A meta-analysis. Gene [Internet]. 2013;518(2):310–5. Available from: http://dx.doi.org/10.1016/j.gene.2013.01.018
10. Dervenis N, Mikropoulou AM, Tranos P, Dervenis P. Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges. Adv Ther. 2017;34(6):1270–82.
11. Stewart MW. A Review of Ranibizumab for the Treatment of Diabetic Retinopathy. Ophthalmol Ther. 2017;6(1):33–47.
12. Maguire MG, Liu D, Glassman AR, Jampol LM, Johnson CA, Baker CW, et al. Visual Field Changes over 5 Years in Patients Treated with Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy. JAMA Ophthalmol. 2020;138(3):285–93.
13. Haritoglou C, Maier M, Neubauer AS, Augustin AJ. Current concepts of pharmacotherapy of diabetic macular edema. Expert Opin Pharmacother [Internet]. 2020;21(4):467–75. Available from: https://doi.org/10.1080/14656566.2020.1713093
14. Gurung RL, FitzGerald LM, McComish BJ, Verma N, Burdon KP. Identifying Genetic Risk Factors for Diabetic Macular Edema and the Response to Treatment. J Diabetes Res. 2020;2020.
15. Al-Kateb H, Mirea L, Xie X, Sun L, Liu M, Chen H, et al. Multiple Variants in Vascular Endothelial Growth Factor (VEGFA) Are Risk Factors for Time to Severe Retinopathy in Type 1 Diabetes. Diabetes [Internet]. 2007 Aug;56(8):2161–8. Available from: http://diabetes.diabetesjournals.org/lookup/doi/10.2337/db07-0376
16. Churchill AJ, Carter JG, Ramsden C, Turner SJ, Yeung A, Brenchley PEC, et al. VEGF Polymorphisms Are Associated with Severity of Diabetic Retinopathy. Investig Opthalmology Vis Sci [Internet]. 2008 Aug 1;49(8):3611. Available from: http://iovs.arvojournals.org/article.aspx?doi=10.1167/iovs.07-1383
17. Nakanishi K, Watanabe C. Single nucleotide polymorphisms of vascular endothelial growth factor gene intron 2 are markers for early progression of diabetic retinopathy in Japanese with type 1 diabetes. Clin Chim Acta [Internet]. 2009 Apr;402(1–2):171–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0009898109000151
18. Tetikoğlu M, Yüksel Z, Aktas S, Sağdik HM, Özcura F. VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema. Int Ophthalmol. 2018;38(6):2381–8.